Literature DB >> 11684013

Targeted disruption of the zetaPKC gene results in the impairment of the NF-kappaB pathway.

M Leitges1, L Sanz, P Martin, A Duran, U Braun, J F García, F Camacho, M T Diaz-Meco, P D Rennert, J Moscat.   

Abstract

Here we have addressed the role that zetaPKC plays in NF-kappaB activation using mice in which this kinase was inactivated by homologous recombination. These mice, although grossly normal, showed phenotypic alterations in secondary lymphoid organs reminiscent of those of the TNF receptor-1 and of the lymphotoxin-beta receptor gene-deficient mice. The lack of zetaPKC in embryonic fibroblasts (EFs) severely impairs kappaB-dependent transcriptional activity as well as cytokine-induced phosphorylation of p65. Also, a cytokine-inducible interaction of zetaPKC with p65 was detected which requires the previous degradation of IkappaB. Although in zetaPKC-/- EFs this kinase is not necessary for IKK activation, in lung, which abundantly expresses zetaPKC, IKK activation is inhibited.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11684013     DOI: 10.1016/s1097-2765(01)00361-6

Source DB:  PubMed          Journal:  Mol Cell        ISSN: 1097-2765            Impact factor:   17.970


  143 in total

Review 1.  NF-kappaB in pancreatic cancer.

Authors:  Guido M Sclabas; Shuichi Fujioka; Christian Schmidt; Douglas B Evans; Paul J Chiao
Journal:  Int J Gastrointest Cancer       Date:  2003

2.  PKCzeta-regulated inflammation in the nonhematopoietic compartment is critical for obesity-induced glucose intolerance.

Authors:  Sang Jun Lee; Ji Young Kim; Ruben Nogueiras; Juan F Linares; Diego Perez-Tilve; Dae Young Jung; Hwi Jin Ko; Susanna M Hofmann; Angela Drew; Michael Leitges; Jason K Kim; Matthias H Tschöp; Maria T Diaz-Meco; Jorge Moscat
Journal:  Cell Metab       Date:  2010-07-07       Impact factor: 27.287

3.  Metabolic stress signaling mediated by mixed-lineage kinases.

Authors:  Anja Jaeschke; Roger J Davis
Journal:  Mol Cell       Date:  2007-08-03       Impact factor: 17.970

4.  Analysis of aPKClambda and aPKCzeta reveals multiple and redundant functions during vertebrate retinogenesis.

Authors:  Shuang Cui; Cécile Otten; Stefan Rohr; Salim Abdelilah-Seyfried; Brian A Link
Journal:  Mol Cell Neurosci       Date:  2007-01-12       Impact factor: 4.314

Review 5.  Protein kinase C iota: human oncogene, prognostic marker and therapeutic target.

Authors:  Alan P Fields; Roderick P Regala
Journal:  Pharmacol Res       Date:  2007-05-05       Impact factor: 7.658

6.  Def-6, a novel regulator of small GTPases in podocytes, acts downstream of atypical protein kinase C (aPKC) λ/ι.

Authors:  Kirstin Worthmann; Michael Leitges; Beina Teng; Marcello Sestu; Irini Tossidou; Thomas Samson; Hermann Haller; Tobias B Huber; Mario Schiffer
Journal:  Am J Pathol       Date:  2013-10-03       Impact factor: 4.307

7.  Dendritic cells treated with resveratrol during differentiation from monocytes gain substantial tolerogenic properties upon activation.

Authors:  Urban Svajger; Natasa Obermajer; Matjaz Jeras
Journal:  Immunology       Date:  2009-11-25       Impact factor: 7.397

8.  Protein kinase C zeta mediates cigarette smoke/aldehyde- and lipopolysaccharide-induced lung inflammation and histone modifications.

Authors:  Hongwei Yao; Jae-woong Hwang; Jorge Moscat; Maria T Diaz-Meco; Michael Leitges; Nandini Kishore; Xiong Li; Irfan Rahman
Journal:  J Biol Chem       Date:  2009-12-11       Impact factor: 5.157

9.  Protein kinase Czeta represses the interleukin-6 promoter and impairs tumorigenesis in vivo.

Authors:  Anita S Galvez; Angeles Duran; Juan F Linares; Peterson Pathrose; Elias A Castilla; Shadi Abu-Baker; Michael Leitges; Maria T Diaz-Meco; Jorge Moscat
Journal:  Mol Cell Biol       Date:  2008-10-27       Impact factor: 4.272

10.  Systematic comparison of gene expression between murine memory and naive B cells demonstrates that memory B cells have unique signaling capabilities.

Authors:  Mary M Tomayko; Shannon M Anderson; Catherine E Brayton; Saheli Sadanand; Natalie C Steinel; Timothy W Behrens; Mark J Shlomchik
Journal:  J Immunol       Date:  2008-07-01       Impact factor: 5.422

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.